SCHEMBL2628445

SCHEMBL2628445

CCCCNCCC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 4/20 0.50
TSHR P16473 2/20 0.48
ALDH1A1 P00352 2/20 0.48
EPHX1 P07099 2/20 0.41
ALOX15 P16050 1/20 0.41
GAA P10253 1/20 0.41
CES1 P23141 2/20 0.41
ADH1B P00325 1/20 0.41
ADH1C P00326 1/20 0.41
ADH1A P07327 1/20 0.41
ADH7 P40394 1/20 0.41
S1PR2 O95136 5/20 0.41
S1PR4 O95977 5/20 0.41
S1PR1 P21453 5/20 0.41
S1PR3 Q99500 5/20 0.41
S1PR5 Q9H228 1/20 0.41
CES2 O00748 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13616526 0.91 PAOX (0.57) PAOXTSHRALDH1A1EPHX1ADH1B
SCHEMBL13616527 0.91 PAOX (0.57) PAOXTSHRALDH1A1EPHX1ADH1B
SCHEMBL6655161 0.91 PAOX (0.57) PAOXTSHRALDH1A1EPHX1ADH1B
SCHEMBL2628444 0.91 PAOX (0.55) PAOXTSHRALDH1A1EPHX1ALOX15
SCHEMBL2628454 0.88 PAOX (0.64) PAOXTSHRALDH1A1EPHX1CES1
SCHEMBL2628452 0.86 PAOX (0.68) PAOXTSHRALDH1A1EPHX1CES1
SCHEMBL23956968 0.85 PAOX (0.59) PAOXTSHRALDH1A1
Butanone SCHEMBL27943570 0.85 ALDH1A1 (0.53) PAOXTSHRALDH1A1EPHX1ALOX15
SCHEMBL15198689 0.85
Acetone SCHEMBL2671636 0.85 TSHR (0.58) PAOXTSHRALDH1A1EPHX1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175037-B2 Neuromedin U derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-03 US disclosed
US-9175037-B2 Neuromedin U derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-03 US disclosed
EP-2418213-B1 NEUROMEDIN U DERIVATIVE TAKEDA PHARMACEUTICAL (JP) 2014-11-19 EP disclosed
US-20120094899-A1 NEUROMEDIN U DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120094899-A1 NEUROMEDIN U DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2418213-A1 NEUROMEDIN U DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2012-02-15 EP disclosed
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-01 US disclosed
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094899-A1 NEUROMEDIN U DERIVATIVE NMUR1, NMUR2, NMBR PAOX 1843/4885TSHR 4221/4885ALDH1A1 3304/4885
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF GNRHR, SHBG, LHCGR PAOX 4032/4885TSHR 1020/4885ALDH1A1 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.